What is ILLUMINA?
Illumina, Inc. is a global leader in genetic and genomic analysis solutions. The company provides cutting-edge sequencing and array-based instruments, consumables, and services essential for research and clinical applications. Its offerings span whole-genome sequencing, targeted resequencing, and innovative diagnostic tools, including the Galleri multi-cancer early detection test. Illumina serves a diverse clientele, including academic institutions, government laboratories, hospitals, and pharmaceutical and biotechnology companies, driving advancements in personalized medicine and disease research.
How much funding has ILLUMINA raised?
ILLUMINA has raised a total of $846M across 2 funding rounds:
Stock Offering
$96M
Debt
$750M
Stock Issuance/Offering (2000): $96M, investors not publicly disclosed
Debt (2023): $750M led by Bank of America
Key Investors in ILLUMINA
Bank of America
Bank of America, a global financial institution, provided debt financing. Their involvement suggests a strong confidence in Illumina's established financial stability and operational capacity.
What's next for ILLUMINA?
The substantial enterprise-level funding, particularly the recent strategic investment, positions Illumina to further accelerate its innovation pipeline and expand its market reach. This capital is expected to fuel advancements in cancer diagnostics, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company's focus on developing comprehensive genomic solutions indicates a strategy aimed at solidifying its leadership in the rapidly evolving biotechnology and diagnostics landscape, potentially through further R&D investment or strategic partnerships.
See full ILLUMINA company page
